sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
|
quinolones
|
caffeine
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s3
|
DDI-DrugBank.d78.s3.p12
|
In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
|
allopurinol
|
azathioprine
|
ADVISE
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s4
|
DDI-DrugBank.d413.s4.p19
|
Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.
|
Diuretic agents
|
epinephrine
|
EFFECT
|
Epinephrine_ddi.xml
|
DDI-DrugBank.d247.s8
|
DDI-DrugBank.d247.s8.p0
|
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
|
HALDOL
|
alcohol
|
EFFECT
|
Haloperidol_ddi.xml
|
DDI-DrugBank.d186.s3
|
DDI-DrugBank.d186.s3.p8
|
If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.
|
phenytoin
|
Norpace CR
|
MECHANISM
|
Disopyramide_ddi.xml
|
DDI-DrugBank.d506.s0
|
DDI-DrugBank.d506.s0.p1
|
Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
|
Ketoconazole
|
methylprednisolone
|
MECHANISM
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s10
|
DDI-DrugBank.d458.s10.p2
|
Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
|
fluoxetine
|
ketoconazole
|
NONE
|
Fluoxetine_ddi.xml
|
DDI-DrugBank.d482.s14
|
DDI-DrugBank.d482.s14.p127
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
clozapine
|
Phenytoin
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p391
|
- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
|
Cholestyramine
|
colestipol
|
NONE
|
Chlorothiazide_ddi.xml
|
DDI-DrugBank.d46.s7
|
DDI-DrugBank.d46.s7.p3
|
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
|
cimetidine
|
CMI
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s6
|
DDI-DrugBank.d238.s6.p14
|
Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.
|
rauwolfia alkaloid
|
MAO inhibitors
|
EFFECT
|
Deserpidine_ddi.xml
|
DDI-DrugBank.d311.s0
|
DDI-DrugBank.d311.s0.p0
|
Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).
|
TORADOL
|
antiepileptic drugs
|
EFFECT
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s18
|
DDI-DrugBank.d3.s18.p4
|
Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
|
Amphetamines
|
antihistamines
|
EFFECT
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s10
|
DDI-DrugBank.d158.s10.p2
|
Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
|
Cyclopropane
|
dopamine
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s8
|
DDI-DrugBank.d325.s8.p2
|
In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.
|
amphotericin B
|
hydrocortisone
|
EFFECT
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s2
|
DDI-DrugBank.d314.s2.p0
|
MAO Inhibitors: DURAGESIC is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics
|
DURAGESIC
|
MAOI
|
ADVISE
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s7
|
DDI-DrugBank.d170.s7.p4
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
erythromycin
|
cisapride
|
INT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p6
|
Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.
|
erythromycin
|
corticosteroids
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s19
|
DDI-DrugBank.d314.s19.p5
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
dalfopristin
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p4
|
Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.
|
Quinolones
|
anticoagulant
|
EFFECT
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s24
|
DDI-DrugBank.d516.s24.p3
|
Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.
|
amphotericin B
|
digitalis
|
EFFECT
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s5
|
DDI-DrugBank.d318.s5.p2
|
- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics
|
sulfapyridine
|
antidiabetics
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s37
|
DDI-DrugBank.d179.s37.p5
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
doxycycline
|
glucocorticoids
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p573
|
However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.
|
STADOL NS
|
sumatriptan
|
MECHANISM
|
Butorphanol_ddi.xml
|
DDI-DrugBank.d246.s3
|
DDI-DrugBank.d246.s3.p2
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
acetaminophen
|
CNS depressants
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p16
|
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
|
antacids
|
aluminum
|
NONE
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s1
|
DDI-DrugBank.d78.s1.p12
|
Oral contraceptives may be less effective while you are taking lymecycline.
|
contraceptives
|
lymecycline
|
EFFECT
|
Lymecycline_ddi.xml
|
DDI-DrugBank.d79.s1
|
DDI-DrugBank.d79.s1.p0
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
tacrolimus
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p99
|
However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
|
coumarin-type anticoagulants
|
anticoagulants
|
NONE
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s1
|
DDI-DrugBank.d415.s1.p8
|
Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
|
WELLBUTRIN
|
steroids
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s22
|
DDI-DrugBank.d5.s22.p3
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
dalfopristin
|
fluoxetine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p124
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
phenytoin
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p14
|
The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected following co-administration with Acamprosate.
|
naltrexone
|
Acamprosate
|
NONE
|
Acamprosate_ddi.xml
|
DDI-DrugBank.d0.s4
|
DDI-DrugBank.d0.s4.p1
|
Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.
|
chloroquine
|
cyclosporin
|
MECHANISM
|
Chloroquine_ddi.xml
|
DDI-DrugBank.d429.s6
|
DDI-DrugBank.d429.s6.p2
|
Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
|
anti-anxiety drugs
|
sparfloxacin
|
NONE
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s1
|
DDI-DrugBank.d86.s1.p16
|
Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy.
|
Carbamazepine
|
Felbatol
|
MECHANISM
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s31
|
DDI-DrugBank.d434.s31.p5
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
salicylates
|
sulfamethoxazole
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1447
|
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
|
EQUETROTM
|
Phenytoin
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s8
|
DDI-DrugBank.d94.s8.p5
|
Sucralfate should not be taken within 2 hours of FACTIVE.
|
Sucralfate
|
FACTIVE
|
ADVISE
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s8
|
DDI-DrugBank.d347.s8.p0
|
Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
|
MYOBLOC
|
aminoglycosides
|
ADVISE
|
Botulinum Toxin Type B_ddi.xml
|
DDI-DrugBank.d323.s0
|
DDI-DrugBank.d323.s0.p0
|
Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.
|
tricyclic antidepressants
|
clidinium
|
EFFECT
|
Clidinium_ddi.xml
|
DDI-DrugBank.d322.s0
|
DDI-DrugBank.d322.s0.p4
|
Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.
|
diazepam
|
valdecoxib
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s48
|
DDI-DrugBank.d328.s48.p0
|
Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with levodopa or carbidopa-levodopa combination products.
|
LODOSYN
|
carbidopa
|
NONE
|
Carbidopa_ddi.xml
|
DDI-DrugBank.d47.s0
|
DDI-DrugBank.d47.s0.p2
|
Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
|
carbamazepine
|
lovastatin
|
NONE
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s24
|
DDI-DrugBank.d522.s24.p33
|
Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.
|
citalopram
|
ketoconazole
|
MECHANISM
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s25
|
DDI-DrugBank.d568.s25.p4
|
Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced 95% neuromuscular block.
|
NIMBEX
|
succinylcholine
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s0
|
DDI-DrugBank.d60.s0.p0
|
Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.
|
ethoxzolamide
|
corticosteroids
|
EFFECT
|
Ethoxzolamide_ddi.xml
|
DDI-DrugBank.d286.s2
|
DDI-DrugBank.d286.s2.p2
|
The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.
|
iron
|
cefdinir
|
NONE
|
Cefdinir_ddi.xml
|
DDI-DrugBank.d420.s7
|
DDI-DrugBank.d420.s7.p1
|
If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.
|
beta-blocker
|
beta blockers
|
NONE
|
Atenolol_ddi.xml
|
DDI-DrugBank.d73.s5
|
DDI-DrugBank.d73.s5.p3
|
Methotrexate: Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.
|
NSAIDs
|
methotrexate
|
MECHANISM
|
Ketoprofen_ddi.xml
|
DDI-DrugBank.d499.s22
|
DDI-DrugBank.d499.s22.p5
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
trifluoperazine
|
triflupromazine
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p286
|
There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.
|
sucralfate
|
anagrelide
|
MECHANISM
|
Anagrelide_ddi.xml
|
DDI-DrugBank.d75.s15
|
DDI-DrugBank.d75.s15.p0
|
In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.
|
digoxin
|
dofetilide
|
EFFECT
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s28
|
DDI-DrugBank.d558.s28.p0
|
Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.
|
amphetamines
|
lithium carbonate
|
EFFECT
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s15
|
DDI-DrugBank.d158.s15.p2
|
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
|
foscarnet
|
non-steroidal anti-inflammatory agents
|
NONE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s3
|
DDI-DrugBank.d260.s3.p41
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
quinolone
|
iron
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p7
|
Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.
|
carbenicillin indanyl sodium
|
probenecid
|
MECHANISM
|
Carbenicillin_ddi.xml
|
DDI-DrugBank.d545.s0
|
DDI-DrugBank.d545.s0.p2
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
atorvastatin
|
trimethoprim
|
NONE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p26
|
Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.
|
Promethazine
|
promethazine
|
NONE
|
Zaleplon_ddi.xml
|
DDI-DrugBank.d324.s12
|
DDI-DrugBank.d324.s12.p1
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Viracept
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p30
|
These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin.
|
contraceptive
|
atorvastatin
|
ADVISE
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s11
|
DDI-DrugBank.d140.s11.p0
|
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine.
|
carbamazepine
|
lamotrigine
|
NONE
|
Levetiracetam_ddi.xml
|
DDI-DrugBank.d212.s14
|
DDI-DrugBank.d212.s14.p6
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
midazolam
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p25
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
antibiotics
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p2
|
Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.
|
quinolone antibiotics
|
aluminum
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s12
|
DDI-DrugBank.d43.s12.p3
|
In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.
|
fluoxetine
|
cimetidine
|
NONE
|
Desloratadine_ddi.xml
|
DDI-DrugBank.d67.s1
|
DDI-DrugBank.d67.s1.p8
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
risperidone
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p9
|
The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
|
troleandomycin
|
clarithromycin
|
NONE
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s2
|
DDI-DrugBank.d170.s2.p22
|
Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
|
Ketoconazole
|
Nefazodone
|
NONE
|
Lovastatin_ddi.xml
|
DDI-DrugBank.d567.s5
|
DDI-DrugBank.d567.s5.p11
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
chlordiazepoxide
|
vitamin C
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p169
|
In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.
|
cyclosporine
|
diltiazem
|
MECHANISM
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s26
|
DDI-DrugBank.d565.s26.p1
|
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
|
selective serotonin reuptake inhibitors
|
sertraline
|
NONE
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s16
|
DDI-DrugBank.d238.s16.p2
|
Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see a href= frova_od.htm#CI CONTRAINDICATIONS).
|
dihydroergotamine
|
FROVA
|
ADVISE
|
Frovatriptan_ddi.xml
|
DDI-DrugBank.d426.s1
|
DDI-DrugBank.d426.s1.p8
|
The effect of corticosteroids on oral anticoagulants is variable.
|
corticosteroids
|
anticoagulants
|
EFFECT
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s7
|
DDI-DrugBank.d487.s7.p0
|
If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.
|
enoxacin
|
digoxin
|
EFFECT
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s8
|
DDI-DrugBank.d395.s8.p4
|
It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.
|
butorphanol
|
erythromycin
|
ADVISE
|
Butorphanol_ddi.xml
|
DDI-DrugBank.d246.s12
|
DDI-DrugBank.d246.s12.p0
|
Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.
|
nonsteroidal anti-inflammatory drugs
|
potassium-sparing diuretics
|
EFFECT
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s16
|
DDI-DrugBank.d529.s16.p1
|
Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
|
Amphetamines
|
norepinephrine
|
EFFECT
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s22
|
DDI-DrugBank.d236.s22.p2
|
Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.
|
Vardenafil
|
ritonavir
|
MECHANISM
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s36
|
DDI-DrugBank.d198.s36.p7
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
delavirdine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p10
|
Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
|
opiates
|
sedatives
|
NONE
|
Brimonidine_ddi.xml
|
DDI-DrugBank.d138.s0
|
DDI-DrugBank.d138.s0.p18
|
The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.
|
phenytoin
|
warfarin
|
NONE
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s8
|
DDI-DrugBank.d172.s8.p19
|
A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.
|
amiodarone
|
indinavir
|
MECHANISM
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s10
|
DDI-DrugBank.d143.s10.p0
|
MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
|
MAO inhibitors
|
furazolidone
|
NONE
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s6
|
DDI-DrugBank.d158.s6.p1
|
H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.
|
famotidine
|
cefditoren pivoxil
|
MECHANISM
|
Cefditoren_ddi.xml
|
DDI-DrugBank.d550.s2
|
DDI-DrugBank.d550.s2.p2
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
VIRACEPT
|
ergot derivatives
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p6
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
anticonvulsants
|
Tegretol
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p251
|
Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.
|
estrogens
|
contraceptives
|
NONE
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s24
|
DDI-DrugBank.d54.s24.p18
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
MAOIs
|
serotoninergic agents
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p9
|
Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
|
WELLBUTRIN
|
antipsychotics
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s22
|
DDI-DrugBank.d5.s22.p0
|
- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives
|
Lofexidine
|
alcohol
|
EFFECT
|
Lofexidine_ddi.xml
|
DDI-DrugBank.d454.s0
|
DDI-DrugBank.d454.s0.p0
|
Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.
|
Acellular vaccines
|
RAPTIVA
|
ADVISE
|
Efalizumab_ddi.xml
|
DDI-DrugBank.d44.s2
|
DDI-DrugBank.d44.s2.p2
|
Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.
|
dantrolene
|
vecuronium
|
EFFECT
|
Dantrolene_ddi.xml
|
DDI-DrugBank.d305.s7
|
DDI-DrugBank.d305.s7.p0
|
The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
|
SSRI
|
TCA
|
EFFECT
|
Amitriptyline_ddi.xml
|
DDI-DrugBank.d99.s9
|
DDI-DrugBank.d99.s9.p0
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
ethionamide
|
thiazide diuretics
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p389
|
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
|
EQUETROTM
|
primidone
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s8
|
DDI-DrugBank.d94.s8.p6
|
Clarithromycin exposure was significantly decreased by nevirapine;
|
Clarithromycin
|
nevirapine
|
MECHANISM
|
Nevirapine_ddi.xml
|
DDI-DrugBank.d270.s18
|
DDI-DrugBank.d270.s18.p0
|
Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.
|
hormonal contraceptives
|
coumarin derivatives
|
EFFECT
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s10
|
DDI-DrugBank.d485.s10.p2
|
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
|
thioxanthenes
|
APOKYN
|
EFFECT
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s3
|
DDI-DrugBank.d357.s3.p43
|
Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
|
colestipol
|
hydrochlorothiazide
|
MECHANISM
|
Hydrochlorothiazide_ddi.xml
|
DDI-DrugBank.d162.s5
|
DDI-DrugBank.d162.s5.p4
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.